This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

In Age Of Patent Expiration, Planning Groups For New Pharma Products Growing In Importance

CHAPEL HILL, N.C., March 9, 2013 /PRNewswire/ -- New product launch groups in the bio-pharmaceutical industry are often faced with dueling pressures of efficiently developing new products with minimum risk and maximum value. In addition, new product commercialization efforts have taken on increased importance in recent years. With the expiration of patents becoming a looming concern across the biopharma industry, individual companies must now, more than ever, find a way to effectively develop new products in a timely manner.

To address various issues related to the critical elements of the new product planning (NPP) function in bio-pharma companies, Best Practices, LLC completed a benchmarking study. The report, " Pharmaceutical New Product Planning: Structure and Activities to Drive Growth and Profitability," addresses the critical roles and structure of NPP groups.

The report provides professionals with actionable insights into critical aspects of the NPP function, such as coordinating regional and global efforts and carrying out dozens of activities that generate commercial insights. Other key study topics include:
  • Benchmarks of NPP group structures, roles, responsibilities, and attributes
  • Assessments of the levers of impact and  effectiveness
  • Definitions of interactions and optimal working relationships between Regional and Global NPP groups
  • Discoveries surrounding the full set of activities NPP groups perform, their timing, intended outcomes, and value for the organization
  • Insights into the future of the NPP function

Best Practices, LLC used both field surveys and interviews to complete this study. In all, 27 New Product Planning leaders at 25 pharma companies across the globe contributed data. In-depth interviews were conducted with leaders from over a dozen of the participating companies.

In addition, Best Practices has found that the role of the NPP function has expanded and has continued to change in recent years. In order to expand upon previous research and benchmarks, Best Practices recently launched a new study that focuses on the importance of the NPP function in the biopharmaceutical industry.

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free


Chart of I:DJI
DOW 17,084.49 +33.74 0.20%
S&P 500 2,014.89 +15.91 0.80%
NASDAQ 4,830.47 +19.6820 0.41%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs